Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma.

Trial Profile

Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications CNS cancer; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms TemPCNSL
  • Most Recent Events

    • 14 Mar 2016 Status changed from recruiting to completed, as per results published in the Journal of Clinical Oncology.
    • 14 Mar 2016 Results published in the Journal of Clinical Oncology
    • 10 Apr 2013 Planned end date changed from 1 Mar 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top